Sort
51,593 grants matching “hepatitis”
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
$645,205Kelly E Dunn · Johns Hopkins University · R01 · FY2015 · DA
Understanding the Multilevel Drivers of Liver Cancer Disparities
$645,058Salma Shariff-Marco · University Of California, San Francisco · R01 · FY2020 · CA
Proteomics of Hepatic Carcinogenesis
$644,829Albert Einstein Col Of Med Yeshiva Univ · R33 · FY2005 · CA
Insulin regulation of hepatic transport
$644,827Rebecca Anne Haeusler · Columbia University Health Sciences · R01 · FY2024 · DK
Pathogenesis of Liver Disease in Hepatitis
$644,772Francis Vincent Chisari · Scripps Research Institute, The · R01 · FY2011 · AI
Quantitative Multimodal Image Guidance for Improved Liver Cancer Treatment
$644,766James S Duncan · Yale University · R01 · FY2017 · CA
Risk Factors for Venous Thromboembolism in the Community
$644,723John A Heit · Mayo Clinic Rochester · R01 · FY2013 · HL
PCB-mediated dysbiosis of the gut microbiome: A missing link in PCB-mediated neurodevelopmental disorders?
$644,712Hans-Joachim Lehmler · University Of Iowa · R01 · FY2020 · ES
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study
$644,646Joshua Aiden Hill · Fred Hutchinson Cancer Center · U01 · FY2023 · CA
Understanding the pathogenesis of elevated androgen induced metabolic dysfunction in females
$644,571Sheng Wu · Johns Hopkins University · R01 · FY2018 · HD
Pathogenesis of Liver Disease in Hepatitis
$644,514Francis Vincent Chisari · Scripps Research Institute, The · R01 · FY2012 · AI
Mechanisms of Interferon-based Therapy and Resistance in HCV Infection
$644,507T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2009 · DK
Molecular Approaches To Vaccine Development For Hepatitis C
$644,507T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2009 · DK
Cell Culture And Animal Models of HCV Infection And HCV-Host interactions
$644,507T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2009 · DK
Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for PLWH who use drugs
$644,505Mary Elizabeth Hawk · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · DA
Deep Mutational Scanning of Monogenic Diabetes Genes to Facilitate Precision Diagnostics for Diabetes
$644,473Anna Louise Gloyn · Stanford University · R01 · FY2024 · DK
Acoustic Radiation Force Based Hepatic Elasticity Quantification and Imaging
$644,429Kathryn R Nightingale · Duke University · R01 · FY2012 · EB
A Sequential Multiple Assignment Randomized Trial of Diet Treatments for Hepatic Steatosis and Cardiometabolic Risk in Adolescents
$644,415Miriam B. Vos · Michigan State University · R61 · FY2025 · HL
Health Promotion Coaching/Vaccine for Homeless Parolees
$644,337Adeline M Nyamathi · University Of California Los Angeles · R01 · FY2011 · DA
Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance
$644,309Gretchen Lano Birbeck · University Of Rochester · R01 · FY2019 · NS
At Risk Hispanic Gangs: Long-Term Consequences for Hiv, Hepatitis and STI
$644,285Avelardo Valdez · University Of Southern California · R01 · FY2011 · DA
Peer Behavioral Activation Utilization to Address Structural Racism and Discrimination and Improve HIV Outcomes in High-Risk, Substance-Using Populations- PUSH
$644,233Elana Simon Rosenthal · University Of Maryland Baltimore · R01 · FY2024 · DA
Early Detection of Hepatocellular Carcinoma
$644,190Laura Beretta · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Bile acid-mediated control of lipid absorption and fatty liver disease
$644,174Thomas A Vallim · University Of California Los Angeles · R01 · FY2024 · DK
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
$644,149Charles M. Rice · Rockefeller University · U19 · FY2016 · AI